2014 in review – CADTH
Michael Wonder - January 2015
www.maestrodatabase.com
The Canadian Drug Expert Committee (CDEC) issued 30 Final Recommendations
for medicines under the Common Drug Review (CDR) process in 2014; these are
summarised below.
- Some of these recommendations were for the same medicine for the same disease (e.g. ingenol mebutate), the same medicine for different diseases (e.g. botulinum toxin type A for migraine and overactive bladder) or the same medicine in different formulations (e.g. aripiprazole tablets (Abilify) and injection (Abilify Maintena)
- 19 were recommended with criteria/condition, three were recommended but only at a lower price and eight were rejected outright
Final recommendations issued by the CDEC
in 2014
|
Month
|
Medicine
|
Disease/condition
|
Sponsor
|
CADTH outcome
|
|
January
|
Ingenol mebutate (Picato)
|
Actinic keratosis
|
Leo
|
Do not list
|
|
February
|
Nil
|
|
|
|
|
March
|
Tocilizumab (Actemra)
|
Juvenile idiopathic arthritis
|
Roche
|
List with criteria/condition
|
|
Rivaroxaban (Xarelto)
|
Venous thromboembolism
|
Bayer
|
List with criteria/condition
|
|
|
Golimumab (Simponi)
|
Ulcerative colitis
|
Janssen-Cilag
|
Do not list at the submitted price
|
|
|
April
|
Aclidinium bromide (Tudorza Genuair)
|
Chronic obstructive pulmonary disease
|
Almirall
|
List with criteria/condition
|
|
Eplerenone (Inspra)
|
Heart failure
|
Pfizer
|
Do not list at the submitted price
|
|
|
May
|
Rotigotine (Neupro)
|
Parkinson’s disease
|
UCB
|
Do not list
|
|
Botulinum toxin type A (Botox)
|
Migraine
|
Allergan
|
Do not list
|
|
|
June
|
Simeprevir sodium (Galexos)
|
Hepatitis C
|
Janssen-Cilag
|
List with criteria/condition
|
|
Teruflunomide (Aubagio)
|
Multiple sclerosis
|
Genzyme
|
Do not list
|
|
|
Saxagliptin hydrochloride with metformin hydrochloride (Komboglyze)
|
Type 2 diabetes mellitus
|
BMS
|
List with criteria/condition
|
|
|
July
|
Golimumab (Simponi)
|
Rheumatoid arthritis
|
Janssen-Cilag
|
List with criteria/condition
|
|
Riociguat (Adempas)
|
Pulmonary artery hypertension
|
Bayer
|
List with criteria/condition
|
|
|
August
|
Sofosbuvir (Sovaldi)
|
Hepatitis C
|
Gilead
|
List with criteria/condition
|
|
Dolutegravir sodium (Tivicay)
|
HIV infection
|
ViiV
|
List with criteria/condition
|
|
|
Fluticasone
furoate with vilanterol trifenatate (Breo Ellipta)
|
Chronic obstructive pulmonary disease
|
GSK
|
List with criteria/condition
|
|
|
September
|
Guanfacine
hydrochloride (Intuniv XR)
|
Attention
deficit hyperactivity disorder
|
Shire
|
Do not list
|
|
Grass pollen
allergen extract (Grastek)
|
Allergic
rhinitis
|
MSD
|
Do not list
|
|
|
October
|
Stiripentol (Diacomit)
|
Epilepsy
|
Biocodex
|
List with criteria/condition
|
|
Aflibercept (Eylea)
|
Age-related
macular degeneration
|
Bayer
|
List with criteria/condition
|
|
|
Ustekinumab (Stelara)
|
Psoriatic arthritis
|
Janssen-Cilag
|
Do not
list at the submitted price
|
|
|
Aripiprazole (Abilify)
|
Depression
|
BMS
|
Do not list
|
|
|
Ingenol
mebutate (Picato)
|
Actinic keratosis
|
Leo
|
Do not list
|
|
|
November
|
Mirabegron (Myrbetriq)
|
Overactive bladder
|
Astellas
|
List with criteria/condition
|
|
Botulinum toxin type A (Botox)
|
Overactive bladder
|
Allergan
|
List with criteria/condition
|
|
|
December
|
Aripiprazole (Abilify Maintena)
|
Schizophrenia
|
Lundbeck
|
List with criteria/condition
|
|
Indacaterol maleate
with glycopyrronium bromide) Ultibro Breezhaler)
|
Chronic
obstructive pulmonary disease
|
Novartis
|
List with criteria/condition
|
|
|
Icatibant acetate (Firazyr)
|
Angioedema
|
Shire
|
List with criteria/condition
|
|
|
Ivacaftor (Kalydeco)
|
Cystic fibrosis
|
Vertex
|
List with criteria/condition
|
|
|
Infliximab (Inflectra)
|
Rheumatoid arthritis, ankylosing
spondylitis, psoriatic arthritis, psoriasis
|
Hospira
|
List with criteria/condition
|
©
Wonder Drug Consulting Pty Ltd, 2015.
No comments:
Post a Comment